Press Releases

Press Releases
Date Title and Summary View
Apr 29, 2010 SUMMIT, N.J., Apr 29, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG): 2010 First Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 31 Percent to $789 Million...
May 5, 2010 SUMMIT, N.J., May 05, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Ninth Annual JMP Securities Research Conference on Monday, May 10, 2010 at 9:30 a.m. PT will be webcast live and will be available in the investor relations section of the company's Web site at www.celge...
May 21, 2010 BOUDRY, Switzerland, May 21, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials evaluating Celgene products in blood cancers and solid tumors at the American Societ...
May 24, 2010 SUMMIT, N.J., May 24, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Citi Global Health Care Conference on Wednesday, May 26, 2010 at 11:00 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. ...
May 27, 2010 SUMMIT, N.J., May 27, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) announced that as a result of Barr Laboratories, Inc., withdrawing its Abbreviated New Drug Application (ANDA) for thalidomide with the US Food and Drug Administration, the US District Court for the District of New Jersey has granted the reque...
May 28, 2010 SUMMIT, N.J., May 28, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at three upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an over...
Jun 4, 2010 BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the ...
Jun 4, 2010 BOUDRY, Switzerland, Jun 04, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ:CELG) today announced researchersat the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma (DLBCL) either ...
Jun 5, 2010 BOUDRY, Switzerland, Jun 05, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced results of a Phase II study of pomalidomide and dexamethasone in multiple myeloma patients who have failed both lenalidomide and bortezomib. Data were presented by Dr. Martha Lacy of the Mayo Clinic during th...
Jun 6, 2010 BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced clinical data from an investigational study of patients with multiple myeloma who were younger than 65 years old and received either lenalidomide (REVLIMID), melphalan and prednisone (MPR) or melphalan plus autolog...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase